Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma.

Kondo, Shunsuke; Sasaki, Mitsuhito; Hosoi, Hiroko; Sakamoto, Yasunari; Morizane, Chigusa; Ueno, Hideki; Okusaka, Takuji

Kondo, Shunsuke; Sasaki, Mitsuhito; Hosoi, Hiroko; Sakamoto, Yasunari; Morizane, Chigusa; Ueno, Hideki; Okusaka, Takuji.

Afiliación

Kondo S; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Sasaki M; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Hosoi H; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Sakamoto Y; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Morizane C; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Ueno H; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Oncotarget ; 9(24): 16883-16890, 2018 Mar 30.

Article en En | MEDLINE | ID: mdl-29682191

Palabras clave

fibrin degradation product; incidence; pancreatic carcinoma; survival; venous thromboembolism

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google